Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases

被引:98
作者
Berezin, Alexander [1 ]
Zulli, Anthony [2 ]
Kerrigan, Steve [3 ]
Petrovic, Daniel [4 ]
Kruzliak, Peter [5 ]
机构
[1] State Med Univ, Dept Internal Med, Zaporozhe, Ukraine
[2] Victoria Univ, Coll Hlth & Biomed, Ctr Chron Dis Prevent & Management, St Albans, Australia
[3] Royal Coll Surgeons Ireland, Mol & Cellular Therapeut Dept, Dublin 2, Ireland
[4] Univ Ljubljana, Sch Med, Dept Histol & Embryol, Ljubljana, Slovenia
[5] Masaryk Univ, St Annes Univ Hosp, Int Clin Res Ctr, Brno 65691, Czech Republic
关键词
Endothelial-derived microparticles; Cardiovascular diseases; Metabolic diseases; Risk stratification; AMERICAN-HEART-ASSOCIATION; TISSUE FACTOR; IN-VITRO; EXTRACELLULAR VESICLES; HYPERTENSIVE PATIENTS; VASCULAR ENDOTHELIUM; ATRIAL-FIBRILLATION; OXIDATIVE STRESS; MISSING LINK; CELLS;
D O I
10.1016/j.clinbiochem.2015.02.003
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Endothelial-derived microparticles (EMPs) are a novel biological marker of endothelium injury and vasomotion disorders that are involved in pathogenesis of cardiovascular, metabolic, and inflammatory diseases. Circulating levels of EMPs are thought to reflect a balance between cell stimulation, proliferation, apoptosis, and cell death. Increased EMPs may be defined in several cardiovascular diseases, such as stable and unstable coronary artery disease, acute and chronic heart failure, hypertension, arrhythmias, thromboembolism, asymptomatic atherosclerosis as well as renal failure, metabolic disorders (including type two diabetes mellitus, abdominal obesity, metabolic syndrome, insulin resistance) and dyslipidemia. This review highlights the controversial opinions regarding impact of circulating EMPs in major cardiovascular and metabolic diseases and summarizes the perspective implementation of the EMPs in risk stratification models. (C) 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:562 / 568
页数:7
相关论文
共 89 条
[1]
Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components [J].
Agouni, Abdelali ;
Andriantsitohaina, Ramaroson ;
Martinez, Maria C. .
CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) :483-492
[2]
Risk Prediction Models for Mortality in Ambulatory Patients With Heart Failure A Systematic Review [J].
Alba, Ana C. ;
Agoritsas, Thomas ;
Jankowski, Milosz ;
Courvoisier, Delphine ;
Walter, Stephen D. ;
Guyatt, Gordon H. ;
Ross, Heather J. .
CIRCULATION-HEART FAILURE, 2013, 6 (05) :881-889
[3]
Comparison of cardiovascular disease risk calculators [J].
Allan, G. Michael ;
Garrison, Scott ;
McCormack, James .
CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (04) :254-265
[4]
[Anonymous], 2013, OXID MED CELL LONGEV, DOI DOI 10.1155/2013/572729
[5]
Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF [J].
Aoki, M ;
Kanamori, M ;
Ohmori, K ;
Takaishi, M ;
Huh, NH ;
Nogami, S ;
Kimura, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (03) :990-995
[6]
Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration [J].
Arraud, N. ;
Linares, R. ;
Tan, S. ;
Gounou, C. ;
Pasquet, J. -M. ;
Mornet, S. ;
Brisson, A. R. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (05) :614-627
[7]
Berezin AE, 2014, J CARDIOL
[8]
Berezin AE, 2014, J DIS MARKERS, V1, P8
[9]
Berezin AE, 2014, INT CARDIOVASC RES J, V8, P116
[10]
Biró É, 2004, J THROMB HAEMOST, V2, P382